Spots Global Cancer Trial Database for A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Official Title: A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
Study ID: NCT01466153
Conditions
Study Description
Brief Summary: The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Birmingham, Alabama, United States
Research Site, Burbank, California, United States
Research Site, La Jolla, California, United States
Research Site, Palm Springs, California, United States
Research Site, Skokie, Illinois, United States
Research Site, Shreveport, Louisiana, United States
Research Site, Baltimore, Maryland, United States
Research Site, Detroit, Michigan, United States
Research Site, Fargo, North Dakota, United States
Research Site, Dayton, Ohio, United States
Research Site, Newark, Ohio, United States
Research Site, Watertown, South Dakota, United States
Research Site, Lubbock, Texas, United States
Research Site, Morgantown, West Virginia, United States
Research Site, Antwerpen, , Belgium
Research Site, Arlon, , Belgium
Research Site, Kortrijk, , Belgium
Research Site, Mons, , Belgium
Research Site, Wilrijk, , Belgium
Research Site, Yvoir, , Belgium
Research Site, Toronto, Ontario, Canada
Research Site, Greenfield Park, Quebec, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Amiens, , France
Research Site, Bayonne, , France
Research Site, Bordeaux, , France
Research Site, Le Mans, , France
Research Site, Libourne Cedex, , France
Research Site, Marseille, , France
Research Site, Nimes, , France
Research Site, Dortmund, , Germany
Research Site, Essen, , Germany
Research Site, Freiburg, , Germany
Research Site, Muenchen, , Germany
Research Site, Wuerzburg, , Germany
Research Site, Haifa, , Israel
Research Site, Ramat Gan, , Israel
Research Site, Bari, , Italy
Research Site, Lecce, , Italy
Research Site, Meldola, , Italy
Research Site, Milano, , Italy
Research Site, Modena, , Italy
Research Site, Napoli, , Italy
Research Site, Orbassano, , Italy
Research Site, Palermo, , Italy
Research Site, Pisa, , Italy
Research Site, Ravenna, , Italy
Research Site, Rimini, , Italy
Research Site, Roma, , Italy
Research Site, San Giovanni Rotondo, , Italy
Research Site, Torino, , Italy
Research Site, Udine, , Italy
Research Site, Gdynia, , Poland
Research Site, Warszawa, , Poland
Contact Details
Name: MedImmune
Affiliation: MedImmune LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
